A Multicenter, Open-Label Safety and Pharmacokinetic Study of DUEXIS (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis

Trial Profile

A Multicenter, Open-Label Safety and Pharmacokinetic Study of DUEXIS (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs Ibuprofen/famotidine (Primary)
  • Indications Juvenile rheumatoid arthritis; NSAID-induced gastrointestinal damage
  • Focus Adverse reactions
  • Sponsors Horizon Pharma
  • Most Recent Events

    • 16 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 16 Jul 2014 Planned End Date changed from 1 Apr 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top